New campaign will highlight Kate Walsh’s journey with dry eye and how finding the right solution of Systane helped her reconnect with what matters Partnership supports the launch of Systane Complete ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE ® PRO Preservative-Free (PF) as ...

May 28 (Reuters) - (This May 28 story has been corrected to say 'eye drop,' not 'liquid medication,' in paragraph 3 and to remove the picture) Eye-care drugmaker Alcon (ALCC.S), opens new tab said on ...

Please provide your email address to receive an email when new articles are posted on . The TRPM8 receptor agonist increases natural tear production as early as day 1. Alcon also launched a campaign ...

Please provide your email address to receive an email when new articles are posted on . NASHVILLE, Tenn. — Alcon’s U.S. pharmaceutical division shared its focus on glaucoma and dry eye with attendees ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE:ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Eye ...

On-Demand Educational Videos Now Available Focused on Dry Eye Disease Mitigation, Measurement, and Management ST. LOUIS, MISSOURI, UNITED STATES, May 10, 2023 ...

“Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care ...

SYSTANE PRO Preservative-Free (PF) is the longest lasting dry eye drop in the SYSTANE portfolio1 SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, ...

The dry eye disease education initiative website also features other evidence-based, practical tools that eye care professionals can use regardless of their geographic location or available resources.

Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR ® (acoltremon ophthalmic ...

Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 45.5 million people in the United States and 1.5 billion globally. 3 Developed exclusively to offer dry eye ...